Levobupivacaina Bioindustria L.I.M. (Levobupivacaine Hydrochloride)

Levobupivacaine works by reversibly binding to the intracellular portion of voltage‑gated sodium channels on nerve membranes. This stabilizes the channels in an inactive state, preventing sodium influx during depolarization, which blocks the generation and propagation of nerve impulses and results in a reversible loss of sensation in the area where it is administered.

The specific dose of Levobupivacaina Bioindustria L.I.M. is determined by the prescribing clinician based on the type of procedure, patient characteristics, and the intended route of administration. Healthcare professionals calculate the appropriate volume and concentration to achieve effective anesthesia while minimizing the risk of toxicity.

Safety data for levobupivacaine in pregnancy and lactation are limited. Use during pregnancy is generally reserved for situations where the benefits outweigh potential risks, and it should be administered by experienced clinicians. Breastfeeding mothers should consult their healthcare provider, as the drug may be excreted in breast milk.

To order Levobupivacaina Bioindustria L.I.M., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After receiving the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine, offering similar potency with a lower risk of cardiotoxicity and central nervous system toxicity. Compared with ropivacaine, it provides a slightly longer duration of action, while maintaining a favorable safety profile. Its choice over alternatives depends on the required duration of anesthesia and the patient’s cardiovascular risk.

Levobupivacaina Bioindustria L.I.M. should be stored at ambient temperature, protected from light and moisture, and kept in its original sealed container. Avoid freezing the solution. Follow any additional handling instructions provided by the manufacturer to maintain sterility and potency.

The product is supplied as a sterile solution for injection. It is administered by qualified healthcare professionals via epidural, infiltration, intrathecal, or other regional techniques. Proper aseptic technique, aspiration before injection, and monitoring of the patient are essential to ensure safe and effective delivery.

Serious risks include cardiac arrhythmias, severe hypotension, central nervous system toxicity such as seizures, prolonged motor block, and allergic reactions that may lead to anaphylaxis. Prompt recognition and management of these events are critical, and patients should be monitored continuously during and after administration.

Levobupivacaina Bioindustria L.I.M. should be avoided in patients with known hypersensitivity to levobupivacaine or other amide local anesthetics, those with severe cardiac conduction disorders, uncontrolled epilepsy, or significant hepatic impairment without appropriate dose adjustment. It is also contraindicated when inadvertent intravascular injection cannot be ruled out.